SGCZ, also known as zeta-sarcoglycan gene, is expressed in brain tissue among other tissues. E-and ζ-sarcoglycan are expressed in the brain, and SGCZ may be involved in processes related to certain disorders [1]. However, no pathogenic SGCZ mutations were found to contribute to the genetic heterogeneity in myoclonus dystonia syndrome (MDS), suggesting it is unlikely to be associated with this disorder [1].

SGCZ has also been associated with other conditions. A genome-wide association study found SGCZ to be associated with prediabetes status change, indicating its potential role in diabetes-related processes [2]. In a study on a unique broiler population, the expression level of SGCZ in abdominal fat tissue differed significantly between fat and lean broilers, showing its possible connection with fatness traits [3]. In breast cancer, SGCZ ranked top for the recurrent copy number alteration (CNA) loss regions, and its expression level was significantly associated with survival outcome in young women with breast cancer [4].

In summary, SGCZ appears to be involved in a variety of biological processes and disease conditions, including those related to movement disorders, diabetes, fat deposition, and breast cancer. Studies on SGCZ contribute to understanding the genetic basis of these conditions, potentially providing new insights for diagnosis, treatment, and prevention.